Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Spyre Therapeutics (SYRE) Return on Sales (2016 - 2024)

Spyre Therapeutics (SYRE) has disclosed Return on Sales for 9 consecutive years, with 529.4% as the latest value for Q1 2024.

  • For the quarter ending Q1 2024, Return on Sales fell 43636.0% year-over-year to 529.4%, compared with a TTM value of 529.4% through Mar 2024, down 46264.0%, and an annual FY2023 reading of 382.38%, down 34639.0% over the prior year.
  • Return on Sales was 529.4% for Q1 2024 at Spyre Therapeutics, down from 382.38% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.56% in Q2 2021 and bottomed at 529.4% in Q1 2024.
  • Average Return on Sales over 4 years is 156.49%, with a median of 98.92% recorded in 2022.
  • The sharpest move saw Return on Sales tumbled -3516bps in 2022, then crashed -43636bps in 2024.
  • Year by year, Return on Sales stood at 5.61% in 2021, then tumbled by -1894bps to 111.88% in 2022, then crashed by -242bps to 382.38% in 2023, then tumbled by -38bps to 529.4% in 2024.
  • Business Quant data shows Return on Sales for SYRE at 529.4% in Q1 2024, 382.38% in Q4 2023, and 279.32% in Q3 2023.